What is Aquestive Therapeutics Inc (AQST) stock price today?

Aquestive Therapeutics Inc (AQST) currently trades at $4.10 per share. The stock has a market capitalization of $497.94M and a P/E ratio of —x.

Is AQST stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Aquestive Therapeutics Inc has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Aquestive Therapeutics Inc's revenue and earnings?

Aquestive Therapeutics Inc has trailing twelve-month (TTM) revenue of $44.55M with profit margins of -188.10%. Earnings per share (EPS) is $-0.78.

Is AQST stock overvalued or undervalued?

Based on our DCF model, Aquestive Therapeutics Inc's intrinsic value is $2.77, representing a margin of safety of -37.91%. The stock currently trades at a P/E of —x.

AQST

Aquestive Therapeutics Inc

NASDAQ: AQST · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$4.10

+1.23% today

Updated 2026-04-30

Market cap

$497.94M

P/E ratio

—

P/S ratio

11.18x

EPS (TTM)

$-0.78

Dividend yield

—

52W range

$2 – $8

Volume

1.7M

Market cap

$497.94M

P/E ratio

—

P/S ratio

11.18x

EPS (TTM)

$-0.78

Dividend yield

—

52W range

$2 – $8

Volume

1.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.0

Growth

5.0

Quality

C+

2.5

Profitability

4.0

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$8.89

+116.83%

12-Month target

—

Intrinsic (DCF)

$2.77

Margin of safety

-37.91%

2 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at -188.10%

- Negative free cash flow $-8.55M

- 37.91% above intrinsic value

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$47.68M	$50.58M	$57.56M	$44.55M	$44.55M
Net income	$-54.41M	$-7.87M	$-44.14M	$-83.78M	$-31.86M
EPS	—	—	—	—	$-0.78
Free cash flow	$-12.31M	$-7.38M	$-35.92M	$-52.99M	$-8.55M
Profit margin	-114.11%	-15.56%	-76.68%	-188.09%	-188.10%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-10	TOTH, A ERNEST JR	Sale	58,254	$4.17
2026-03-10	KORCZYNSKI, SHERRY	Sale	15,741	$4.17
2026-03-10	JUNG, CASSIE	Sale	45,791	$4.17

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
AQST	$497.94M	22	4.0	2.5	4.0	5.0	-37.91%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Aquestive Therapeutics Inc trades at $4.10. Our Smart Value Score of 22/100 indicates the stock is weak. TTM revenue stands at $44.55M. with profit margins at -188.10%. Our DCF model estimates intrinsic value at $2.77.

Frequently asked questions

What is Aquestive Therapeutics Inc's stock price?

Aquestive Therapeutics Inc (AQST) trades at $4.10.

Is Aquestive Therapeutics Inc overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell). DCF value $2.77.

What is the price target of Aquestive Therapeutics Inc (AQST)?

The analyst target price is $8.89, representing +116.8% upside from the current price of $4.10.

What is the intrinsic value of Aquestive Therapeutics Inc (AQST)?

Based on our DCF model, intrinsic value is $2.77, a -37.9% margin of safety versus $4.10.

What is Aquestive Therapeutics Inc's revenue?

TTM revenue is $44.55M.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio11.18x

ROE—

Beta1.53

50D MA$4.10

200D MA$4.86

Shares out0.12B

Float0.11B

Short ratio—

Avg volume1.7M

Performance

1 week-5.53%

1 month+1.99%

3 months+18.16%

YTD-36.53%

1 year—

3 years—

5 years—

Compare

AQST vs LLY →AQST vs JNJ →AQST vs ABBV →Stock screener →